Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Subscribe To Our Newsletter & Stay Updated
